Intellia Therapeutics, Inc. (NASDAQ:NTLA) Holdings Decreased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 93.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,295 shares of the company's stock after selling 543,237 shares during the period. Price T Rowe Associates Inc. MD's holdings in Intellia Therapeutics were worth $459,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Sterling Capital Management LLC increased its stake in Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after purchasing an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in Intellia Therapeutics in the 4th quarter worth about $40,000. Resona Asset Management Co. Ltd. purchased a new position in Intellia Therapeutics in the 4th quarter worth about $43,000. Jones Financial Companies Lllp increased its stake in Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after purchasing an additional 2,280 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its stake in Intellia Therapeutics by 80.6% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock worth $60,000 after purchasing an additional 2,299 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NTLA. Truist Financial dropped their price target on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Barclays dropped their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. The Goldman Sachs Group restated a "sell" rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. JPMorgan Chase & Co. restated a "neutral" rating and set a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, Wolfe Research upgraded Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective for the company in a research report on Monday, April 21st. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.90.

Intellia Therapeutics Trading Down 2.7%

Shares of NTLA stock opened at $8.32 on Wednesday. The stock has a 50-day moving average of $8.11 and a 200-day moving average of $10.91. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.18. The stock has a market cap of $861.81 million, a price-to-earnings ratio of -1.53 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. During the same quarter in the previous year, the company posted ($1.12) EPS. The firm's revenue was down 42.6% on a year-over-year basis. Sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.